Skip to main content
. 2021 Feb 4;10(3):R116–R124. doi: 10.1530/EC-20-0489

Figure 1.

Figure 1

Graphic illustrating checkpoint inhibitor action to shift immune response. Without treatment self and tumour reacting T-cells are driven to anergy and unchecked tumour growth. Following treatment, the anti-cancer immune response is upregulated leading to controlled tumour growth, but increased risk of self-reacting T cells contributing to immune-related adverse events.